We are delighted to announce that Sandra Johnson will join Richmond Pharmacology as its new Director for Commercial Project Management, focused on enhancing the company’s procurement and outsourcing functions.  Sandra joined Richmond Pharmacology in September 2022 from Medicines for Malaria Venture and will work alongside the company’s senior management team and CEO, Dr Jorg Taubel, to improve procurement and outsourcing to further enhance first-in-human and adaptive clinical trials.

Sandra has over 20 years of experience in the life science sector, including at Roche and Novartis, and she has an extensive understanding of clinical procurement. During her time at Medicines for Malaria Venture, she was Director for Outsourcing & Relationship Management. Prior to this, Sandra served as Outsourcing and Procurement Consultant at Minerve Services, and before that as Team Leader Procurement, Global Product Strategy at Roche and Senior CRO Manager at Novartis, where she outsourced clinical research services for Phase I-IV trials and oversaw its strategic outsourcing initiative.

Sandra is currently a member of the Global Health Clinical Consortium and the Pharmaceutical Contracts Management Group (PCMG).

Please join us in welcoming Sandra in our team!

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event